Fig. 3From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastasesAssociation between progression-free survival (PFS) and a absolute decrease in volume between baseline MRI and day + 1 MRI, and b relative decrease in volume between baseline MRI and day + 1 MRIBack to article page